

Vik Meadows

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6694277/publications.pdf>

Version: 2024-02-01

22
papers

313
citations

933447

10
h-index

940533

16
g-index

23
all docs

23
docs citations

23
times ranked

268
citing authors

#	ARTICLE	IF	CITATIONS
1	Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2 ^{-/-} mice and human cholangiocarcinoma tumorigenesis. <i>Hepatology</i> , 2018, 68, 1042-1056.	7.3	50
2	Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis Through Farnesoid X Receptor Signaling. <i>Hepatology</i> , 2021, 74, 2684-2698.	7.3	35
3	The interplay between mast cells, pineal gland, and circadian rhythm: Links between histamine, melatonin, and inflammatory mediators. <i>Journal of Pineal Research</i> , 2021, 70, e12699.	7.4	31
4	Mast Cells Promote Nonalcoholic Fatty Liver Disease Phenotypes and Microvesicular Steatosis in Mice Fed a Western Diet. <i>Hepatology</i> , 2021, 74, 164-182.	7.3	25
5	Bile Acid Receptor Therapeutics Effects on Chronic Liver Diseases. <i>Frontiers in Medicine</i> , 2020, 7, 15.	2.6	23
6	Functional Role of the Secretin/Secretin Receptor Signaling During Cholestatic Liver Injury. <i>Hepatology</i> , 2020, 72, 2219-2227.	7.3	18
7	Biliary damage and liver fibrosis are ameliorated in a novel mouse model lacking l-histidine decarboxylase/histamine signaling. <i>Laboratory Investigation</i> , 2020, 100, 837-848.	3.7	18
8	Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes. <i>Hepatology</i> , 2021, 74, 1845-1863.	7.3	16
9	Biliary Epithelial Senescence in Liver Disease: There Will Be SASP. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 803098.	3.5	15
10	Amelioration of Large Bile Duct Damage by Histamine-2 Receptor Vivo-Morpholino Treatment. <i>American Journal of Pathology</i> , 2020, 190, 1018-1029.	3.8	13
11	Feedback Signaling between Cholangiopathies, Ductular Reaction, and Non-Alcoholic Fatty Liver Disease. <i>Cells</i> , 2021, 10, 2072.	4.1	13
12	Alcoholic liver disease and mast cells: What's your gut got to do with it?. <i>Liver Research</i> , 2019, 3, 46-54.	1.4	9
13	Knockout of the Tachykinin Receptor 1 in the Mdr2 ^{-/-} (Abcb4 ^{-/-}) Mouse Model of Primary Sclerosing Cholangitis Reduces Biliary Damage and Liver Fibrosis. <i>American Journal of Pathology</i> , 2020, 190, 2251-2266.	3.8	9
14	Melatonin receptor 1A, but not 1B, knockout decreases biliary damage and liver fibrosis during cholestatic liver injury. <i>Hepatology</i> , 2022, 75, 797-813.	7.3	9
15	Cyclic AMP Signaling in Biliary Proliferation: A Possible Target for Cholangiocarcinoma Treatment?. <i>Cells</i> , 2021, 10, 1692.	4.1	8
16	Mast cells in liver disease progression: An update on current studies and implications. <i>Hepatology</i> , 2022, 75, 213-218.	7.3	7
17	Molecular Mechanisms Linking Risk Factors to Cholangiocarcinoma Development. <i>Cancers</i> , 2022, 14, 1442.	3.7	6
18	The Effects of Taurocholic Acid on Biliary Damage and Liver Fibrosis Are Mediated by Calcitonin-Gen-Related Peptide Signaling. <i>Cells</i> , 2022, 11, 1591.	4.1	6

#	ARTICLE	IF	CITATIONS
19	ASBT Vivoâ€Morpholino Decreases Hepatic Mast Cell, Fibrosis and Biliary Senescence in Mdr2 ^{-/-} Mice. FASEB Journal, 2021, 35, .	0.5	0
20	Mast Cell Signaling Regulates Biliary Farnesoid X Receptor and Apical Sodium Bile Acid Transporter Expression During Cholestatic Liver Injury. FASEB Journal, 2020, 34, 1-1.	0.5	0
21	The protective effects of estrogen on biliary and liver damage are independent of ER ^α signaling in female Mdr2 ^{-/-} mice. FASEB Journal, 2022, 36, .	0.5	0
22	Mast Cells Contribute to Hepatic Neurokinin1 Receptor Signaling, Subsequent Biliary Damage and Peribiliary Fibrosis Via TGF ^β 1 Signaling in MDR2 ^{-/-} Mouse Model of Primary Sclerosing Cholangitis. FASEB Journal, 2022, 36, .	0.5	0